- Conditions
- Neoplasm Malignant
- Interventions
- Cabazitaxel (XRP6258)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 14
- States / cities
- La Jolla, California • Loma Linda, California • Washington D.C., District of Columbia + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 9,115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Biliary Cholangitis, PBC
- Interventions
- Volixibat, Placebo
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 44
- States / cities
- Coronado, California • Los Angeles, California • Sacramento, California + 38 more
- Conditions
- Prostate Cancer
- Interventions
- Casodex, Eulexin, LHRH agonist, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 1,579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2022
- U.S. locations
- 241
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
- Conditions
- Schizophrenia
- Interventions
- Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Secukinumab (AIN457), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 21
- States / cities
- Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Loop
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- Not listed
- Enrollment
- 1,212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- HIV Infections
- Interventions
- Thymopentin, Stavudine, Zidovudine, Zalcitabine, Didanosine
- Drug
- Lead sponsor
- Immunobiology Research Institute
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 33 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Lunsekimig, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 942 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 75
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Surprise, Arizona + 61 more
- Conditions
- Atopic Dermatitis
- Interventions
- Nemolizumab
- Biological
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- Fountain Valley, California • Fremont, California • Jacksonville, Florida + 7 more
- Conditions
- Triple Negative Breast Cancer, PD-L1 Negative
- Interventions
- Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 130
- States / cities
- Tucson, Arizona • Burbank, California • La Jolla, California + 92 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- CP-690,550
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 147
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 116 more
- Conditions
- Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
- Interventions
- LB1908
- Biological
- Lead sponsor
- Legend Biotech USA Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Detroit, Michigan • Hackensack, New Jersey + 6 more
- Conditions
- Epilepsy, Epilepsy, Partial
- Interventions
- LAMICTAL extended-release
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 70
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 60 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab, Antihistamine, Methylprednisolone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 25
- States / cities
- Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more
- Conditions
- HIV
- Interventions
- Epic Allies App Intervention, Epic Allies - Control Branch
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 16 Years to 24 Years · Male only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Chicago, Illinois • New Orleans, Louisiana + 2 more
- Conditions
- Bladder Cancer, Non-muscle Invasive Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- Photocure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Iowa City, Iowa • Ann Arbor, Michigan + 2 more
- Conditions
- Endometrial Cancer
- Interventions
- Lifileucel
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 9 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, peginterferon alfa-2a [Pegasys]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 75 more
- Conditions
- Muscular Atrophy
- Interventions
- LY2495655, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Laguna Hills, California • Lakewood, Colorado + 13 more
- Conditions
- Aortic Aneurysm
- Interventions
- EndoAnchor™, endovascular treament
- Device · Procedure
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,090 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
- Conditions
- Cardiothoracic Surgery, Vascular Surgery
- Interventions
- Placebo, ABT-719
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 20
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 16 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
- Interventions
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 12,024 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more